North America Epigenomics Market 2018-2026

North America Epigenomics Market 2018-2026

KEY FINDINGS

A major share of the global epigenomics market was captured by the North American region in the year 2017. By the end of the forecast period of 2018-2026, the North America epigenomics market is expected to further grow at a CAGR of 17.51%.

MARKET INSIGHTS

U.S and Canada are the major geographies studied for this market. While the US presently leads this market in terms of revenue generation, it is the Canada epigenomics market that is expected to exhibit the highest CAGR by the end of 2026. Global companies and biotech firms have increased their investments in academic and industrial translational activities in Canada in the recent years. This has paved the way for enhanced epigenomics research in the country. However, complex regulatory frameworks and the lack of reimbursement provision in insurance for epigenomics are factors restraining the overall North America epigenomics market progression.

COMPETITIVE INSIGHTS

Market companies like Roche Holding Ag, Merck Sharp & Dohme, Glaxosmithkline, Johnson & Johnson, Naturewise Biotech & Medicals Corp, Abbott Laboratories, Epigentek, Rubicon Genomics, Astellas Pharmaceuticals, Agilent Technologies, Epigenomics Ag, Affymetrix, Bayer Ag, Novartis Pharma Ag, Orchid Chemicals & Pharmaceuticals Limited, Illumina Inc and Celgene Corp are involved in epigenetic research.


1. Research Scope
1.1. Study Goals
1.2. Scope Of The Market Study
1.3. Who Will Find This Report Useful?
1.4. Study And Forecasting Years
2. Research Methodology
2.1. Sources Of Data
2.1.1. Secondary Data
2.1.2. Primary Data
2.2. Top-down Approach
2.3. Bottom-up Approach
2.4. Data Triangulation
3. Executive Summary
3.1. Market Summary
3.2. Key Findings
3.2.1 North America Leads The Global Market By Capturing The Largest Revenue Share
3.2.2 Reagents Form A Major Part Of The Epigenomics Market, By Product
3.2.3 Epigenetics Diagnosis Is A Major Part Of Epigenomic Market, And Personalized Medicines Is Showing A Dynamic Growth
3.2.4 Oncology Is The Primary Application While Non-oncology Is Showing A Better Growth
4. Market Dynamics
4.1. Market Definition & Scope
4.2. Market Drivers
4.2.1. Advancement In The Prevalence Of Cancer And Other Chronic Diseases
4.2.2. Rise In The Ageing Population
4.2.3. Decline In The Sequencing Costs And Time
4.2.4. Escalation In Funding For Research & Development
4.2.5. Need For Better Cancer Therapies
4.2.6. Growth In Personalized Medicine
4.2.7. Increasing Importance Of Epigenetic Technology
4.3. Market Restraints
4.3.1 Inefficiency In Identification And Validation Of Biomarker
4.3.2 Presence Of Complex Regulatory Framework
4.3.3 Lack Of Reimbursement Provision In Insurance For Epigenomic
4.4. Market Opportunities
4.4.1 Increasing Awareness About Epigenomics
4.4.2 Growing Applications Of Epigenetics In Personalized Medicine And Targeted Therapy
4.4.3 Use Of Epigenomic In Non-oncology Applications
4.5. Market Challenges
4.5.1 Scarcity Of Trained Professionals
4.5.2 High Cost Of Instruments And Consumables
5. Market By Product
5.1. Reagents
5.2. Kits
5.3. Instruments
5.4. Enzymes
5.5. Services
6. Market By Technology
6.1. Dna Methylation
6.2. Histone Methylation & Acetylation
6.3. Microrna Modification
7. Market By Application
7.1. Oncology
7.1.1. Dna Methyltransferase Inhibitors
7.1.2. Histone Deacetylase Inhibitors
7.2. Non-oncology
8. Market By Application Area
8.1. Diagnosis
8.2. Drug Discovery
8.3. Therapy Optimization
8.4. Prognosis
9. Market By Segment
9.1. Epigenetic Diagnosis
9.1.1. Cancer
9.1.2. Neuro
9.1.2.1. Mental Retardation
9.1.2.2. Alzheimer’s Disease
9.1.2.3. Depression
9.1.2.4. Other
9.1.3. Cardiovascular
9.1.3.1. Vascular Disease
9.1.3.2. Heart Failure
9.1.3.3. Others
9.1.4. Inflammatory & Autoimmune Disease
9.1.4.1. Rheumatoid Arthritis
9.1.4.2. Diabetes
9.1.4.3. Lupus
9.1.4.4. Multiple Sclerosis
9.1.4.5. Inflammatory Bowel Diseases
9.1.5. R&D
9.1.5.1. Dna Methylation In Cancer Detection
9.1.5.2. Identification Of Epigenetic Biomarkers For Diagnosis And Prediction
9.1.5.3. Mechanisms Of Epigenetic Gene Silencing
9.2. Personalized Medicine
9.2.1. Cancer Treatment
9.2.1.1. Lung Cancer
9.2.1.2. Solid Cancers
9.2.1.3. Gastric Cancer
9.2.1.4. Haematological Cancers
9.2.1.5. Others
9.2.2. Neurological Disorders
9.2.2.1. Mental Retardation
9.2.2.2. Huntington’s Disease
9.2.2.3. Parkinson’s Disease
9.2.2.4. Alzheimer’s Disease
9.2.2.5. Depression
9.2.3. Cvd
9.2.4. Others
9.2.4.1. Rheumatoid Arthritis
9.2.4.2. Diabetes
9.2.4.3. Myelodysplastic Syndromes
9.2.4.4. Multiple Sclerosis
9.2.4.5. Obesity
9.2.4.6. Inflammatory Bowel Diseases
9.2.4.7. Lupus
9.2.4.8. Other
9.3. Epigenetic Therapies
9.4. Biomarkers
9.4.1. Dna Methylation For Cancer Detection
9.4.2. Histonic Modification As Biomarker In Cancer Detection
9.4.2.1. Histone Methylation
9.4.2.2. Histone Acetylation
9.4.3. Noncoding Rnas
9.4.4. Mirnas
9.4.5. Chromatin Remodeling
10. Key Analytics
10.1. Porter’s Five Force Model
10.1.1. Threat Of New Entrants
10.1.2. Threat Of Substitute
10.1.3. Bargaining Power Of Suppliers
10.1.4. Bargaining Power Of Buyers
10.1.5. Threat Of Competitive Rivalry
10.2. Opportunity Matrix
10.3. Vendor Landscape
11. Geographical Analysis
11.1. North America
11.1.1. United States
11.1.2. Canada
12. Company Profiles
12.1. Abbott Laboratories
12.2. Affymetrix
12.3. Agilent Technologies
12.4. Astellas Pharmaceuticals
12.5. Bayer Ag
12.6. Celgene Corp.
12.7. Epigenomics Ag
12.8. Epigentek
12.9. Glaxosmithkline
12.10. Illumina Inc.
12.11. Johnson & Johnson
12.12. Laboratory Corp. Of America Holdings
12.13. Merck Sharp & Dohme
12.14. Novartis Pharma Ag
12.15. Tbg Diagnostics Limited
12.16. Rubicon Genomics
12.17. Roche Holding Ag
Table List
Table 1 North America Epigenomic Market, By Country, 2018-2026, (In $ Ten Thousand)
Table 2 North America Epigenomic Market, By Product, 2018-2026, (In $ Ten Thousand)
Table 3 North America Epigenomic Market, By Technology, 2018-2026, (In $ Ten Thousand)
Table 4 North America Epigenomic Market, By Application, 2018-2026, (In $ Ten Thousand)
Table 5 North America Epigenomic Market, By Application Area, 2018-2026, (In $ Ten Thousand)
Table 6 North America Epigenomic Market, By Segment, 2018-2026, (In $ Ten Thousand)
Table 7 North America Epigenomic Market, By Epigenetic Diagnosis, 2018-2026 (In $ Ten Thousand)
Table 8 North America Epigenetic Diagnosis Market, By Neuro, 2018-2026, (In $ Ten Thousand)
Table 9 North America Epigenetic Diagnosis Market, By Cardiovascular, 2018-2026, (In $ Ten Thousand)
Table 10 North America Epigenetic Diagnosis Market, By Inflammatory & Autoimmune Disease, 2018-2026, (In $ Ten Thousand)
Table 11 North America Epigenetic Diagnosis Market, By R&D, 2018-2026, (In $ Ten Thousand)
Table 12 North America Epigenomic Market, By Personalized Medicine, 2018-2026, (In $ Ten Thousand)
Table 13 North America Personalized Medicine Market, By Cancer Treatment, 2018-2026, (In $ Ten Thousand)
Table 14 North America Personalized Medicine Market, By Neurological Disorders, 2018-2026 (In $ Ten Thousand)
Table 15 North America Personalized Medicine Market, By Others, 2018-2026 (In $ Ten Thousand)
Table 16 North America Epigenomics Market, By Biomarkers, 2018-2026 (In $ Ten Thousand)
Table 17 Opportunity Matrix
Table 18 Vendor Landscape
Table 19 North America Epigenomic Market, By Country, 2018-2026 (In $ Ten Thousand)
Figure List
Figure 1 North America Epigenomic Market Share, By Segment 2017 & 2026 (%)
Figure 2 North America Revenue Estimation ($ Ten Thousand)
Figure 3 Reagents Estimated Revenue ($ten Thousand)
Figure 4 Epigenetic Diagnosis Estimated Revenue ($ Ten Thousand)
Figure 5 Personalized Medicines Estimated Revenue ($ Ten Thousand)
Figure 6 Oncology Revenue Estimation ($ Ten Thousand)
Figure 7 Non-oncology Revenue Estimation ($ Ten Thousand)
Figure 8 North America Epigenomic Market, By Reagents, 2018-2026, (In $ Ten Thousand)
Figure 9 North America Epigenomic Market, By Kits, 2018-2026, (In $ Ten Thousand)
Figure 10 North America Epigenomic Market, By Instruments, 2018-2026, (In $ Ten Thousand)
Figure 11 North America Epigenomic Market, By Enzymes, 2018-2026, (In $ Ten Thousand)
Figure 12 North America Epigenomic Market, By Services, 2018-2026, (In $ Ten Thousand)
Figure 13 North America Epigenomic Market, By Dna Methylation, 2018-2026, (In $ Ten Thousand)
Figure 14 North America Epigenomic Market, By Histone Methylation And Acetylation, 2018-2026, (In $ Ten Thousand)
Figure 15 North America Epigenomic Market, By Micro-rna Modification, 2018-2026, (In $ Ten Thousand)
Figure 16 North America Epigenomic Market, By Oncology, 2018-2026, (In $ Ten Thousand)
Figure 17 North America Epigenomic Market, By Dna Methyltransferase Inhibitors, 2018-2026, (In $ Ten Thousand)
Figure 18 North America Epigenomic Market, By Histone Deacetylase Inhibitors, 2018-2026, (In $ Ten Thousand)
Figure 19 North America Epigenomic Market, By Non-oncology, 2018-2026, (In $ Ten Thousand)
Figure 20 North America Epigenomic Market, By Diagnosis, 2018-2026, (In $ Ten Thousand)
Figure 21 North America Epigenomic Market, By Drug Discovery, 2018-2026, (In $ Ten Thousand)
Figure 22 North America Epigenomic Market, By Therapy Optimization, 2018-2026, (In $ Ten Thousand)
Figure 23 North America Epigenomic Market, By Prognosis, 2018-2026, (In $ Ten Thousand)
Figure 24 North America Epigenomic Market, By Epigenetic Diagnosis, 2018-2026, (In $ Ten Thousand)
Figure 25 North America Epigenomic Market, By Epigenetic Diagnosis-cancer, 2018-2026, (In $ Ten Thousand)
Figure 26 North America Epigenomic Market, By Neuro-mental Retardation, 2018-2026, (In $ Ten Thousand)
Figure 29 North America Epigenomic Market, By Neuro- Alzheimer’s Disease, 2018-2026, (In $ Ten Thousand)
Figure 30 North America Epigenomic Market, By Neuro- Depression, 2018-2 026, (In $ Ten Thousand)
Figure 31 North America Epigenomic Market, By Neuro- Other, 2018-2026, (In $ Ten Thousand)
Figure 32 North America Epigenomic Market, By Cardiovascular-vascular Disease, 2018-2026, (In $ Ten Thousand)
Figure 33 North America Epigenomic Market, By Cardiovascular- Heart Failure, 2018-2026, (In $ Ten Thousand)
Figure 34 North America Epigenomic Market, By Cardiovascular- Others, 2018-2026, (In $ Ten Thousand)
Figure 35 North America Epigenomic Market, By Rheumatoid Arthritis, 2018-2026, (In $ Ten Thousand)
Figure 36 North America Epigenomic Market, By Diabetes, 2018-2026, (In $ Ten Thousand)
Figure 37 North America Epigenomic Market, By Lupus, 2018-2026, (In $ Ten Thousand)
Figure 38 North America Epigenomic Market, By Multiple Sclerosis, 2018-2026, (In $ Ten Thousand)
Figure 39 North America Epigenomic Market, By Inflammatory Bowel Diseases, 2018-2026, (In $ Ten Thousand)
Figure 40 North America Epigenomic Market, By Dna Methylation In Cancer Detection, 2018-2026, (In $ Ten Thousand)
Figure 41 North America Epigenomic Market, By Identification Of Epigenetic Biomarkers For Diagnosis And Prediction, 2018-2026, (In $ Ten Thousand)
Figure 42 North America Epigenomic Market, By Mechanisms Of Epigenetic Gene Silencing, 2018-2026, (In $ Ten Thousand)
Figure 43 North America Epigenomic Market, By Cancer Treatment, 2018-2026, (In $ Ten Thousand)
Figure 44 North America Epigenomic Market, By Lung Cancer, 2018-2026, (In $ Ten Thousand)
Figure 45 North America Epigenomic Market, By Solid Cancers, 2018-2026, (In $ Ten Thousand)
Figure 46 North America Epigenomic Market, By Gastric Cancer, 2018-2026, (In $ Ten Thousand)
Figure 47 North America Epigenomic Market, By Hematological Cancers, 2018-2026, (In $ Ten Thousand)
Figure 48 North America Epigenomic Market, By Others, 2018-2026, (In $ Ten Thousand)
Figure 49 North America Epigenomic Market, By Mental Retardation, 2018-2026, (In $ Ten Thousand)
Figure 50 North America Epigenomic Market, By Huntington’s Disease, 2018-2026, (In $ Ten Thousand)
Figure 51 North America Epigenomic Market, By Parkinson’s Disease, 2018-2026, (In $ Ten Thousand)
Figure 52 North America Epigenomic Market, By Alzheimer’s Disease, 2018-2026, (In $ Ten Thousand)
Figure 53 North America Epigenomic Market, By Depression, 2018-2026, (In $ Ten Thousand)
Figure 54 North America Epigenomic Market, By Cvd, 2018-2026, (In $ Ten Thousand)
Figure 55 North America Epigenomic Market, By Rheumatoid Arthritis, 2018-2026, (In $ Ten Thousand)
Figure 56 North America Epigenomic Market, By Diabetes, 2018-2026, (In $ Ten Thousand)
Figure 57 North America Epigenomic Market, By Myelodysplastic Syndromes, 2018-2026, (In $ Ten Thousand)
Figure 58 North America Epigenomic Market, By Multiple Sclerosis, 2018-2026, (In $ Ten Thousand)
Figure 59 North America Epigenomic Market, By Obesity, 2018-2026, (In $ Ten Thousand)
Figure 60 North America Epigenomic Market, By Inflammatory Bowel Diseases, 2018-2026, (In $ Ten Thousand)
Figure 61 North America Epigenomic Market, By Lupus, 2018-2026, (In $ Ten Thousand)
Figure 62 North America Epigenomic Market, By Other, 2018-2026, (In $ Ten Thousand)
Figure 63 North America Epigenomic Market, By Epigenetic Therapies, 2018-2026, (In $ Ten Thousand)
Figure 64 North America Epigenomic Market, By Biomarkers, 2018-2026, (In $ Ten Thousand)
Figure 65 North America Epigenomic Market, By Dna Methylation, 2018-2026, (In $ Ten Thousand)
Figure 66 North America Epigenomic Market, By Histonic Modification, 2018-2026, (In $ Ten Thousand)
Figure 67 North America Epigenomic Market, By Histone Methylation, 2018-2026, (In $ Ten Thousand)
Figure 68 North America Epigenomic Market, By Histone Acetylation, 2018-2026, (In $ Ten Thousand)
Figure 69 North America Epigenomic Market, By Noncoding Rnas, 2018-2026, (In $ Ten Thousand)
Figure 70 North America Epigenomic Market, By Mirnas, 20 18-2026, (In $ Ten Thousand)
Figure 71 North America Epigenomic Market, By Chromatin Remodeling, 2018-2026, (In $ Ten Thousand)
Figure 72 Porter’s Five Force Model
Figure 73 North America Epigenomic Market, Country Outlook, 2018-2026, (In $ Ten Thousand)
Figure 74 United States Epigenomic Market, 2018-2026 (In $ Ten Thousand)
Figure 75 Canada Epigenomic Market, 2018-2026 (In $ Ten Thousand)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook